Pemetrexed Plus Platinum Versus Docetaxel Plus Platinum As First-line Treatment For Advanced Non-small Cell Lung Cancer: A Systematic Review

Objective: Evaluate the efficacy and toxicity of pemetrexed plusplatinum (PP) regimen and docetaxel plus platinum (DP) regimen asfirst line treatment for patients with advanced non small cell lung cancer(NSCLC).Methods: Search relevant randomized controlled trials from Pubmed,Medline, Cochrane Library, FMJS, CNKI, VIP, CBMdisc. At the same timeconsult relevant bibliography. Use RevMan5.0provided by the CochraneCollaboration to perform meta analysis.Results:8RCTs involving674patients are identified. There are nostatistical differences between PP and DP regimens in response rate,dysfunction of liver, fatigue and anorexia. But disease control rate,1yearsurvival rate, median survival time, hematological toxicity, gastrointestinalreaction and alopecia are significantly different.Conclusions: As the current evidence shows, PP regimen as first linetreatment for advanced NSCLC has good clinical efficiency. PP regimen can improve the disease control rate,1year survival rate and extendmedian survival time. It can also reduce the incidence of hematologicaltoxicity, gastrointestinal reaction, alopecia and other side effects.